Shane Neibart, Resident Physician at Harvard Radiation Oncology Program, shared aan update from The Lancet Oncology, on X, adding:
“Great study!
- SCRT v LCCRT for OP, build on prior evid of LCCRT enabling OP in ACOSOG Z6041 ph II
- QOL comparisons to surgery paradigm (non-randomized)
- Mesorectum only RT (No internal iliac)
Caution
- Not a comparison to TNT
- Early outcomes
- <20% T3.”
Quoting The Lancet Oncology:
“Online now.”
Title: Chemoradiotherapy versus short-course radiotherapy for response-adapted organ preservation in early-stage and intermediate-stage rectal cancer (STAR-TREC): 12-month results of an international, multicentre, open-label, parallel-group, randomised, phase 2/3 trial
Authors: Simon P Bach, David Sebag-Montefiore, Victoria Homer, Alexandra Gilbert, Ane Appelt, Ian Geh, Geerard L Beets, Jacobus Burger, Eva Angenete, Gunnar Baatrup, Karen-Lise Garm Spindler, Karin Haustermans, Fabian Holman, Ellen M Kerkhof, Emily Lam, Stephan Korsgen, Anna Martling, Albert Wolthuis, Issam Al-Najami, Pehr Lind, Femke P Peters, Mark Teo, Nicholas P West, Simon Gates, Corrie A M Marijnen, Johannes H W de Wilt.
Read the full article.
Title: STAR-TREC and TESAR trials: strengthening the evidence for organ preservation in rectal cancer
Authors: Emmanouil Fokas, Ralf-Dieter Hofheinz.
Read the full article.
This also can be interesting: TESAR Trial: Adjuvant ChemoRT vs Completion TME After Local Excision for Early Rectal Cancer
